Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan

Published:2019-09 Issue:9 Volume:82 Page:693-698
ISSN:1726-4901
Container-title:Journal of the Chinese Medical Association
language:en
Short-container-title:

Author:

Wu Sih-Hsien,Chu Chi-Jen,Su Chien-Wei,Lin Chung-Chi,Lee Shou-Dong,Wang Yuan-Jen,Lee Fa-Yauh,Huang Yi-Hsiang,Hou Ming-Chih

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference40 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.;Lancet Gastroenterol Hepatol,2017

2. Global epidemiology and genotype distribution of the hepatitis C virus infection.;Gower;J Hepatol,2014

3. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.;Mohd Hanafiah;Hepatology,2013

4. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants.;Chen;J Formos Med Assoc,2007

5. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey.;Sun;J Med Virol,1999

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose;Pharmacology Research & Perspectives;2021-06-20

2. A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia;Hepatitis Monthly;2021-04-05

3. Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment;The Kaohsiung Journal of Medical Sciences;2020-11-05

4. Outstanding research paper awards of the Journal of the Chinese Medical Association in 2019;Journal of the Chinese Medical Association;2020-10-26

5. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations;Journal of the Formosan Medical Association;2020-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3